Investment By Board of Directors in Company Tops $3 Million
ST. PETERSBURG, Fla., Feb. 4 /PRNewswire-FirstCall/ -- Nutraceutical
Clinical Laboratories International, Inc. (OTC Pink Sheets: NCCL), a
preservative and nutraceutical products company, today announced that it has
appointed Samuel E. Hudgins, a financial services executive and consultant,
and Kathy A. Joiner, a senior commercial banker, to its Board of Directors.
"Sam and Kathy are two great additions to our Board," said Gary L.
Harrison, Chairman and Chief Executive Officer of NCCL. "They both are
skilled executives with impeccable credentials, and the Board will benefit
from their experience and judgment. The Board's strong commitment to NCCL's
future is evidenced by the more than $3 million we have collectively invested
in the Company over the past 18 months."
Mr. Hudgins serves on the Board of Directors and Executive Committee of
Atlantic American Corporation, an insurance holding company. He also provides
management and financial advisory services to a variety of clients through
Hudgins Consulting, a firm he formed in 1997. Previously, Mr. Hudgins was a
member of the Board of Directors of The Wachovia Funds from 1992 until 2002.
He also was President of Atlantic American and Chairman of its three insurance
companies. Mr. Hudgins also served as Vice Chairman and Chief Executive
Officer of Rhodes, Inc., a retail furniture chain subsidiary of Atlantic
American. He began his career at Arthur Andersen in 1951, where he held a
number of senior leadership positions prior to his retirement in 1986.
Ms. Joiner is the President of the Thomasville, Georgia division of
SunTrust Bank, one of the largest commercial banking organizations in the U.S.
In this position, which she has held since 1999, Ms. Joiner is responsible for
managing the division's operations and growing its market share. Prior to
joining SunTrust, Ms. Joiner worked at The Citizens and Southern National
Bank, which merged in 1991 with NationsBank, which is now known as Bank of
America. Ms. Joiner is active in many civic, charitable and professional
organizations, and recently was selected as an Honorary Member of the
President's Advisory Committee for Small Business.
The Company also announced that its founder, Paul L. Simmons, has resigned
from its Board to pursue other interests. NCCL's Board thanked Mr. Simmons
for his contributions to the Company.
Mr. Hudgins and Ms. Joiner join the following executives on NCCL's Board
of Directors (more information about each Board Member is available on the
Company's Web site at http://www.nutradata.com ):
* Gary L. Harrison, Chairman and Chief Executive Officer
* William J. Catacosinos, Ph.D., Vice Chairman
* Robert Gillham, Director
* Richard Goldfarb, M.D., Director and President and Chief Operating
Officer of NCCL's Medical Division
* Philip E. Pearce, Director
* George J. Sideris, Director
About Nutraceutical Clinical Laboratories International, Inc.
Incorporated in 1999, Nutraceutical Clinical Laboratories International,
Inc. is a company that researches, manufactures and markets preservative and
nutraceutical products. Based in St. Petersburg, Florida, the Company has a
Preservative Division and a Medical Division, which includes the wholly owned
subsidiary Health Care Direct Services, Inc. (HCD). The Preservative unit
focuses on developing, manufacturing and marketing NuPreserv(TM), a
preservative that extends the shelf life of food products and beverages. The
Medical unit focuses on developing NuPreserv's medical applications and
manufacturing and distributing HCD's nutraceutical products to more than
20,000 independent and chain-store pharmacies across the U.S. More
information about Nutraceutical Clinical Laboratories International, Inc. is
available on the Company's Web site at http://www.nutradata.com .
CAUTIONARY NOTE: Statements contained in this press release that are not
historical facts are forward-looking statements as the term is defined in the
Private Securities Litigation Reform Act of 1995. All forward-looking
statements are subject to risks and uncertainties which could cause actual
results to differ from the forward-looking statements contained in this
release and which may affect the Company's prospects in general.